Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

To join this study, you need to have moderate to severe plaque psoriasis. Your doctor must think that you would normally be considered for treatments like light therapy or other body-wide medicines for your psoriasis, including ustekinumab.

Crucially, you also need to have at least one risk factor for heart disease. This could include if you currently smoke, have been diagnosed with high blood pressure or high cholesterol, have diabetes (type 1 or type 2), or have a family history of heart disease at a younger age. Having a past heart event like a heart attack or stroke, or obesity, would also qualify.

However, you can't join if you've had a recent heart attack, stroke, or blood clot within the last 3 months, or if you have unstable heart disease that needs immediate attention. You also cannot have had active cancer or certain types of cancer within the last 5 years, unless it was a successfully treated minor skin cancer or early cervical cancer.

The detailed involvement in this study isn't fully described here, but generally, taking part in a clinical trial involves receiving either deucravacitinib or ustekinumab as per the study’s plan. You would have regular visits to the clinic for health checks, blood tests, and to discuss any side effects or changes in your psoriasis. These visits would likely involve physical exams and questions about your health and how you are feeling. Throughout the study, your health will be carefully monitored. The total duration of the study is designed for long-term observation, meaning it could last for an extended period, potentially several years.